tbuckley/cabot-search huggingface dataset:
Recent advances in biomaterials for 3D scaffolds: A review
Authors: Maria P. Nikolova, Murthy S. Chavali
Journal: Bioactive Materials (2019)

Considering the advantages and disadvantages of biomaterials used for the production of 3D scaffolds for tissue engineering, new strategies for designing advanced functional biomimetic structures have been reviewed. We offer a comprehensive summary of recent trends in development of single- (metal, ceramics and polymers), composite-type and cell-laden scaffolds that in addition to mechanical support, promote simultaneous tissue growth, and deliver different molecules (growth factors, cytokines, bioactive ions, genes, drugs, antibiotics, etc.) or cells with therapeutic or facilitating regeneration effect. The paper briefly focuses on divers 3D bioprinting constructs and the challenges they face. Based on their application in hard and soft tissue engineering, in vitro and in vivo effects triggered by the structural and biological functionalized biomaterials are underlined. The authors discuss the future outlook for the development of bioactive scaffolds that could pave the way for their successful imposing in clinical therapy.
Time From Submission of Johns Hopkins University Trial Results to Posting on ClinicalTrials.gov
Authors: Anthony Keyes, Evan Mayo-Wilson, Nidhi Atri, Aliya Lalji, Prince S. Nuamah, Oswald Tetteh, Daniel E. Ford
Journal: JAMA Internal Medicine (2019)

Comparison of Availability of Trial Results in ClinicalTrials.gov and PubMed by Data Source and Funder Type
OA07.07 Quality of Life (QoL) Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018
Authors: M.L. Reale, E. De Luca, P. Lombardi, L. Marandino, C. Zichi, D. Pignataro, E. Ghisoni, R. Di Stefano, A. Mariniello, E. Trevisi, G. Leone, L. Muratori, A. La Salvia, C. Sonetto, P. Bironzo, M. Aglietta, S. Novello, G. Scagliotti, F. Perrone, M. Di Maio
Journal: Journal of Thoracic Oncology (2019)
Abstract 3747: Radium 223 inhibits prostate cancer in bone via zonal cytotoxicity
Authors: Eleonora Dondossola, Stefano Casarin, Claudia Paindelli, Elena De-Juan-Pardo, Dietmar Hutmacher, Christopher Logothetis, Peter Friedl
Journal: Cancer Research (2019)

Abstract Bone metastases are the initial site of progression and account for many complications experienced by men with metastatic prostate cancer (PCa), with limited therapeutic options. Targeting the bone environment has recently resulted in the approval of Radium-223 (Rad-223), a new life-prolonging therapy for patients with metastatic castrate-resistant prostate cancer. Rad-223 is a rare earth metal radioisotope that displays chemical properties similar to calcium, becomes enriched in bone after in vivo administration and emits alpha particles with locally high energy but limited penetrance in tissues (&amp;lt;100 µm). Confoundingly, the clinical response to Radium-223 is often followed by detrimental relapse and progression, and whether Radium-223 causes tumor-cell directed cytotoxicity in vivo remains unclear. We hypothesized that limited radiation penetrance in situ defines outcome and addressed the principles discriminating Radium-223 efficacy from failure by combining 3D intravital microscopy, in silico modeling and end-point analysis in preclinical PCa models in bone. Radium-223 induced profound but zonally confined cancer cell lethality along the bone interface (200-300 µm), while the more distant tumor core remained unperturbed. As consequence, macro-lesions persisted and grew, whereas micro-tumors in the bone niche showed severe growth delay or eradication. The relative inefficacy in controlling large tumors points to application of Radium-223 in secondary prevention of early bone-metastatic disease and regimens co-targeting the tumor core or broadening the zonal toxicity. Citation Format: Eleonora Dondossola, Stefano Casarin, Claudia Paindelli, Elena De-Juan-Pardo, Dietmar Hutmacher, Christopher Logothetis, Peter Friedl. Radium 223 inhibits prostate cancer in bone via zonal cytotoxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3747.
Research spending on cancers doesn't match their death rates
Journal: BMJ (2002)

Scientists in the United Kingdom believe that an innovative "map" of how money is spent on cancer research could help to streamline research on cancer, target areas of underfunding, and advance new discoveries in the field.The National Cancer Research Institute has produced what is thought to be the world's first detailed breakdown of cancer research in any country.It estimates that funding of more than £250m ($390m; 400m) from 15 leading charities and government organisations goes towards cancer research in the United Kingdom every year.The analysis of some 1800 projects shows that most of the funding is channelled into the country's biggest killers from cancer: cancers of the breast, colon and rectum, and prostate.However, some cancers that cause few deaths attract a large share of the funding, while others that have a high death toll get little research attention.This is especially true for lung cancer and leukaemia.Although lung cancer accounted for 22% of deaths from cancer in 2000, it received just 3% of available funding.Conversely, leukaemia, which accounted for 3% of deaths from cancer,
MA23.05 A Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM)
Authors: A. Wozniak, B. Schneider, G. Kalemkerian, R. Daly, W. Chen, J. Ventimiglia, M. Nagasaka, M. Zauderer
Journal: Journal of Thoracic Oncology (2019)
Polio: WHO declares type 3 poliovirus eradicated after 31 year campaign
Authors: Owen Dyer
Journal: BMJ (2019)

Type 3 wild poliovirus has become the third human pathogen in history to be eradicated, following smallpox and type 2 wild poliovirus. Only type 1 wild poliovirus remains in circulation, the World Health Organization announced on 24 October.

The news is a morale boost for the global campaign to eradicate polio, which has had a difficult year as vaccine refusals and deadly attacks on polio workers have hampered immunisation efforts. Overall, the disease has made a small comeback since 2017, with case numbers now rising for the first time in decades.

Certifying the disappearance of a polio type is a long and painstaking process overseen by the Global Commission for the Certification of the Eradication of Poliomyelitis. It is seven years since type 3 poliovirus was last identified in the wild, in Nigeria. Over 1.5 million faecal or sewage samples have since been tested around the world, with no type 3 viruses found.

Declaring eradication triggers a global effort to account for and secure all samples held in laboratories. The same process occurred …
Abstract 16281: Comparison of Guideline Recommendations and Trial Evidence for Statins in Primary Prevention of Cardiovascular Disease in a Population-based Cohort: The Rotterdam Study
Authors: Jelena Pavlovic, Jasper J Brugts, Jaap W Deckers, Maryam Kavousi, Albert Hofman, Bruno H Stricker, Oscar H Franco, Maarten J Leening
Journal: Circulation (2015)

Introduction: The 2013 ACC/AHA and the 2012 European Society of Cardiology (ESC) guidelines recommend lipid-lowering treatment for primary prevention based on cardiovascular disease (CVD) risk. Randomized clinical trials for statin use in primary prevention, however, included participants with specific risk factor profiles. Hypothesis: For most individuals in the general population recommended for primary prevention of CVD with statins direct trial evidence is available. Evidence of benefit may be available for persons currently not recommended treatment. Methods: We used data from 8925 participants (57% women), aged 45-79, free of CVD from the population-based Rotterdam Study to compare treatment recommendations by the ACC/AHA and ESC guidelines, with eligibility for any of 10 major statin trials. Results: The ACC/AHA guidelines recommend statin use in 3196 (83.2%) men and 2611 (51.4%) women; the ESC guidelines in 1992 (51.8%) men and 1702 (33.4%) women (95.3% overlap with ACC/AHA). A total of 2243 (58.4%) men and 2438 (48.0%) women met the eligibility criteria for at the least one trial. Guideline recommendations and trial eligibility overlapped for 2245 (25.2%) participants (Figure). A total of 2480 (27.8%) participants would be considered for statin initiation solely by the ACC/AHA and/or ESC guidelines, while 1180 (13.2%) would have been eligible for at the least one trial and would not be recommended for statin therapy based on the guidelines (Figure). Correspondence of guideline recommendations with trial eligibility varied greatly by trial, with virtual complete alignment for trials done in individuals with diabetes, while for trials done in individuals with hypercholesterolemia alignment was poor. Conclusions: For the majority of persons recommended for lipid-lowering therapy in primary prevention, efficacy of statins has been established. Statins have been proven efficacious in many persons currently not recommended for treatment.
P1.13-14 Prognosis and Clinicopathologic Characteristics of Skip N2 Metastasis in Completely Resected Non-Small Cell Lung Cancer
Authors: T. Tsuboi, D. Eriguchi, D. Nemoto, J. Samejima, T. Nagashima, H. Ito, H. Nakayama
Journal: Journal of Thoracic Oncology (2019)
P1.17-04 Multicenter Observational Study of Node-Negative Non-Small Cell Lung Cancer Patients Who Are Excluded from a Clinical Trial
Authors: H. Sakurai, Y. Goto, K. Yoh, K. Takamochi, T. Shukuya, T. Hishida, M. Tsuboi, K. Yoshida, Y. Ohde, S. Okumura, Y. Ohashi, H. Kunitoh
Journal: Journal of Thoracic Oncology (2019)
EP1.14-46 The KIF5B-RET Fusion as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma
Authors: Y. Zhu, W. Wang, C. Xu, Q. Zhang, W. Zhuang, K. Du, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
ICOSLG-mediated regulatory T cell expansion and IL-10 production promote progression of glioblastoma
Authors: Ryoichi Iwata, Joo Hyoung Lee, Mikio Hayashi, Umberto Dianzani, Kohei Ofune, Masato Maruyama, Souichi Oe, Tomoki Ito, Tetsuo Hashiba, Kunikazu Yoshimura, Masahiro Nonaka, Yosuke Nakano, Lyse Norian, Ichiro Nakano, Akio Asai
Journal: Neuro-Oncology (2019)

Targeting immune checkpoint proteins has recently gained substantial attention due to the dramatic success of this strategy in clinical trials for some cancers. Inducible T-cell co-stimulator ligand (ICOSLG) is a member of the B7 family of immune regulatory ligands, expression of which in cancer is implicated in disease progression due to regulation of antitumor adaptive immunity. Although aberrant ICOSLG expression has been reported in glioma cells, the underlying mechanisms that promote glioblastoma (GBM) progression remain elusive.Here, we investigated a causal role for ICOSLG in GBM progression by analyzing ICOSLG expression in both human glioma tissues and patient-derived GBM sphere cells (GSCs). We further examined its immune modulatory effects and the underlying molecular mechanisms.Bioinformatics analysis and GBM tissue microarray showed that upregulation of ICOSLG expression was associated with poor prognosis in patients with GBM. ICOSLG expression was upregulated preferentially in mesenchymal GSCs but not in proneural GSCs in a tumor necrosis factor-α/nuclear factor-kappaB-dependent manner. Furthermore, ICOSLG expression by mesenchymal GSCs promoted expansion of T cells that produced interleukin-10. Knockdown of the gene encoding ICOSLG markedly reduced GBM tumor growth in immune competent mice, with a concomitant downregulation of interleukin-10 levels in the tumor microenvironment.Inhibition of the ICOSLG-inducible co-stimulator axis in GBM may provide a promising immunotherapeutic approach for suppressing a subset of GBM with an elevated mesenchymal signature.
Physician and practice characteristics influencing tumor board attendance: Results from the provider survey of the Los Angeles Women's Health Study
Authors: K. Scher, D. M. Tisnado, D. Rose-Ash, A. Rastegar, J. Adams, C. Y. Ko, P. A. Ganz, K. L. Kahn
Journal: Journal of Clinical Oncology (2009)

e17501 Background: Coordination of care has grown in importance with the advent of new modalities of treatment requiring specialized expertise. In cancer care, multidisciplinary approaches have shown improvements in quality of care and patient satisfaction. Tumor boards provide a mechanism for improving coordination of care. We evaluated physician and practice characteristics that predict frequency of tumor board attendance. Methods: This cross-sectional study utilizes data obtained by surveying physicians of a population-based sample of women with incident breast cancer. Physicians were queried regarding tumor board attendance, specialty (medical oncologist [MO], radiation oncologist [RO], surgeon indicating that the hospital at which most breast cancer surgeries are performed has an American College of Surgeons accredited program [ACOSSg] and surgeon without such affiliation [non-ACOSSg]), physician characteristics (gender, race, teaching involvement, patient volume, number of offices, ownership interest), and practice setting (practice type, size, reimbursement). Univariate, bivariate, and multivariate analyses were performed for the dependent variable characterizing provider report of frequency of tumor board meeting attendance. Results: Most surveyed physicians (83%) report attending tumor board weekly (58%) or monthly (25%). Weekly participation was reported by 63%, 92%, 47%, and 32% of MOs, ROs, ACOSSgs, and non-ACOSSgs (p &lt; 0.01). Specialty and higher patient volumes are significant predictors of more frequent attendance, after adjustment for practice size and type. In comparison to the most prevalent specialty category (low volume ACOSSgs), high volume MOs attend more (p = 0.01), and low volume non-ACOSSgs attend less frequently (p = 0.00). Conclusions: Tumor board attendance implies increased participation in multidisciplinary care, but specific subsets of providers are less frequent users. This not only has implications for choosing providers, but also for efforts to increase attendance. Tumor board agendas and formalized institution wide policies could be designed to further engage low frequency attendees as a means to promote multidisciplinary care and improve health outcomes. [Table: see text]
Plans to improve primary care in Wales must be implemented more quickly, says watchdog
Authors: Abi Rimmer
Journal: BMJ (2019)

Implementation of a new primary care model for Wales has been patchy, and not enough has been done to educate patients on the new ways of working, says a report from the auditor general for Wales.

The auditor’s role is to examine how authorities in Wales manage and spend public money, including how they achieve value in delivering public services.

Adrian Crompton, auditor general, said that a new primary care model for Wales had evolved in the past few years, promoting the development of multi-professional primary care teams to reduce …
P2.06-01 STELLAR Trial: Radiological Response Patterns of TTFields Plus Chemotherapy in First-Line Treatment of Malignant Pleural Mesothelioma
Authors: F. Grosso, J. Aerts, R. Ramlau, S. Cedres, M. Mencoboni, J. Van Meerbeeck, R. Dziadziuszko, D. Planchard, A. Chella, L. Crino, M. Krzakowski, G.L. Ceresoli, U. Weinberg
Journal: Journal of Thoracic Oncology (2019)
OA12.01 PCI for Radically Treated Non-Small Cell Lung Cancer: A Meta-Analysis Using Updated Individual Patient Data of Randomized Trials
Authors: W. Witlox, D. De Ruysscher, B. Lacas, C. Le Pechoux, J. Pignon, M. Guckenberger, A. Sun, M. Redman, S. Wang, C. Hu, V. Van Der Noort, N. Li, H. Van Tinteren, H. Groen, M. Joore, B. Ramaekers
Journal: Journal of Thoracic Oncology (2019)
Prognostic Significance of Cytogenetic Abnormalities in Patients with Philadelphia-Negative ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: A CIBMTR Analysis
Authors: Aleksandr Lazaryan, Michelle Dolan, Mei-Jie Zhang, Hai-Lin Wang, Veronika Bachanova, Marcos De Lima, Brenda M. Sandmaier, Daniel J. Weisdorf
Journal: Blood (2017)
P2.16-19 Real World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation - A Multicenter Observational Study
Authors: M. Kimura, K. Nishino, Y. Yano, M. Mori, H. Suzuki, T. Hirashima, S. Minami, K. Komuta, T. Shiroyama, I. Nagatomo, F. Imamura
Journal: Journal of Thoracic Oncology (2019)
MA01.05 Progress of Accompanying GGN Beyond Pulmonary Resection for Non-Small Cell Lung Cancer
Authors: K. Lee, H.R. Kim, S. Park, D.K. Kim, Y. Kim, S. Choi, G.D. Lee, Y.H. Jeong, J.K. Yun, Y. Chong
Journal: Journal of Thoracic Oncology (2019)
P2.04-86 Efficacy of Ipilimumab in Combination with Chemotherapy for First-Line Treatment of Advanced Lung Cancer
Authors: T. Htut, A. Tun, S. Swarup, A. Sultan, F. Mogollon-Duffo, N. Jahan, N. Adhikari, Y. Oo, A. Thida, H. Aung, W. Thi, K. Panigrahi, L. Tijani, K. Thein
Journal: Journal of Thoracic Oncology (2019)
EP1.01-07 Definitive Results of a Clinical and Molecular Multicentric Characterization of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer
Authors: J. Moreno-Rubio, S. Ponce, R. Alvarez, M.E. Olmedo, S. Falagan, X. Mielgo Rubio, F. Navarro, P. Cruz, L. Cabezon-Gutierrez, M. Muñoz Fernandez De Leglaría, A.B. Enguita, M. Cebollero, A. Benito, I. Alemany, C. Del Castillo, A. Ramirez De Molina, E. Casado, R. Ramos, G. Colmenarejo, M. Sereno
Journal: Journal of Thoracic Oncology (2019)
Iso-oxazole-Fludelone (KOS-1803) as a potent and efficacious microtubule-stablization epothilone against xenograft tumors.
Authors: Ting-Chao Chou, Xiu-Guo Zhang, Huajin Dong, Ziyang Zhong, Li Feng, Yong Li, Michael Sherrill, Pieter Timmermanns, Robert Johnson, Samuel Danishefsky
Journal: Cancer Research (2008)

1402  17-Iso-oxazole-26-F3-9,10-dehydro-12,13-desoxy-epothilone B (Iso-Fludelone or KOS-1803) designed by diverted total synthesis based on pharmacological property leads has been shown to be a strong candidate compound for clinical development. In vitro, it has an IC50 of 0.27nM against CCRF-CEM cells, which is 4-fold more potent than paclitaxel (Taxol®). It is 638-fold and 637-fold more potent than Taxol against drug-resistant CCRF-CEM/Taxol and CCRF-CEM/Vinblastine cells, respectively. It showed microtubule-stabilization activity slightly exceeding Taxol. When compared with the 1st generation dEpoB and the 2nd generation dehydelone, KOS-1803 is metabolically stable in mouse plasma and efficacious when delivered as either a 6 hr-i.v. infusion or oral administration; has improved water solubility (non-Cremophor formulation); has increased bioavailability and tissue penetration for prolonged tumor tissue drug retention; and demonstrates favorable pharmacokinetic and pharmacodynamic properties. The critical-optimal conditions for efficacious therapy and low toxicity are 6 hr-i.v. infusion at 25-30mg/kg every 12-16 days for a maximum of 3 doses. In human xenograft tumors in nude mice: for CCRF-CEM/Taxol at optimal conditions, KOS-1803 led to 4/4 complete remission (CR) without any relapses for over 3 months, whereas Taxol had no therapeutic effect, and Cytoxan suppressed tumor without a CR. For CCRF-CEM xenograft, KOS-1803, Taxol and Cytoxan all achieved CR, but 2/4 of Cytoxan treated relapsed one month later. For the primary pancreatic adenocarcinoma Bx-CP-3 xenograft, KOS-1803 (25mg/kg, Q12Dx3, i.v. infusion) led to complete tumor suppression and shrinkage but no CR, whereas Taxol (20mg/kg, Q2Dx8, i.v.) and Gemcitabine (40mg/kg, Q2Dx10, i.v.) suppressed tumor growth only 90% and 60%, respectively. For hepatoma Hep xenograft, KOS-1803 (30mg/kg, Q16x2, i.v. infusion) led to complete tumor growth suppression and shrinkage but no CR, whereas Taxol (25mg/kg, Q2Dx4, i.v.) and Cytoxan (50mg/kg, Q2Dx3, i.v.) and 5-fluorouracil (40mg/kg, QDx5, i.v.), led to only 15%, 55%, and 30% tumor growth suppression, respectively. The above data are in addition to early superior therapeutic results for KOS-1803 against mammary MX-1 (i.v. infusion or oral), neuroblastoma SK-NAS, lung A549 and A549/Taxol, ovarian SK-OV-3, mammary MCF-7/Adr xenografts over other chemotherapeutic agents (Chou et al. Proc. AACR 47: 115, 2006, Zhong et al. ibid. 48: 341, 2007 and Chou, ibid. 48: 342, 2007). Thus, so far, we have not been able to find any other cancer therapeutic agent that is even approximate to KOS-1803 in overall therapeutic efficacy in xenograft experimental systems. [Supported by NIH-NCI grant CA28824, SKI-Institutional General Fund, and Kosan Biosciences].
P2.10-03 Prevalence of Tobacco Use Disorder in Patients Diagnosed with Lung Cancer and Their Tobacco Use Characteristics
Authors: C.K. Park, C.D. Yeo, J.S. Kim, S.H. Lee, Y.K. Kim, S.H. Paik, J.E. Jeong, D.J. Kim, S.J. Kim
Journal: Journal of Thoracic Oncology (2019)
FOXP3 protects conventional human T cells from premature restimulation-induced cell death
Authors: Kelsey Voss, Camille Lake, Christopher R. Luthers, Nathaniel M. Lott, Batsukh Dorjbal, Swadhinya Arjunaraja, Bradly M. Bauman, Anthony R. Soltis, Gauthaman Sukumar, Clifton L. Dalgard, Andrew L. Snow
Journal: Cellular and Molecular Immunology (2019)
Mandatory Use of Perioperative Disposable Jackets—Things We Do for No Good Reason
Authors: Paul M. Maggio, Mary T. Hawn
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
P2.18-19 Radiological and Pathological Response to the Induction of Surgery in the NSCLC Stage III
Authors: F. Casas, D. Sánchez, M. Boada, D. Munoz, C. Cabrera, R. Martin, D. Martinez, P. Paredes, I. Vollmer, K. Cortes, T. Barreto, G. Oses, M. Parera, S. Castillo
Journal: Journal of Thoracic Oncology (2019)
P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
Authors: J. Rotow, A. Urisman, C. Mccoach, T. Jahan, T. Bivona, K. Jones, A. Gupta, H. Do, J. Riess, D. Aisner, R. Doebele, D. Jablons, J. Kratz, C. Blakely
Journal: Journal of Thoracic Oncology (2019)
QuantiFERON®-CMV for Immune-Monitoring in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Enrico Morello, Elisabetta Pagani, Vladia Monsurrò, Irene Cavattoni, Silvia Coin, Clara Larcher, Giuseppe Tridente, Sergio Cortelazzo
Journal: Blood (2008)
P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC
Authors: J. Yun, H.N. Kang, S. Lee, C. Park, S. Jeong, M.H. Hong, H.R. Kim, M. Thayu, J.C. Curtin, R.E. Knoblauch, M.V. Lorenzi, A. Roshak, B.C. Cho
Journal: Journal of Thoracic Oncology (2019)
EP1.18-10 Bilateral Mediastinal Lymphadenectomy Is Associated with Better Survival in Stage IA-IIIB Non-Small Cell Lung Cancer
Authors: A. Turna, H. Kara, M. Agkoç, B. Sözen, M. Işcan, E. Erşen, K. Kaynak
Journal: Journal of Thoracic Oncology (2019)